Otsuka eyes Sprycel synergies as it takes back Asian Busulfex rights
This article was originally published in Scrip
Otsuka Pharmaceutical will regain all rights to its specialist oncology product IV Busulfex (busulfan) from current Asian licensee Kyowa Hakko Kirin when the two firms' contract expires at the end of March next year.
You may also be interested in...
Chi-Med’s surufatinib has come up trumps in a second trial in neuroendocrine tumors, after the monitoring committee recommended an early halt following achievement of its PFS target in the pancreatic setting.
Corporate consolidation and specialization were major threads running through the 2010s in Japan. Reimbursement pricing issues continued to dominate the policy sphere while new forms of therapy benefited from positive regulatory reforms.
BeiGene licenses antibody therapeutics for Castleman’s disease and high-risk neuroblastoma.